Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Biotechnol J ; 19(5): e2300671, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38797725

RESUMEN

Cell line development for production of vaccine antigens or therapeutic proteins typically involves transfection, selection, and enrichment for high-expressing cells. Enrichment methods include minipool enrichment, antibody-based enrichment, and enrichment based on co-expressed fluorescent biosensor proteins. However, these methods have limitations regarding labor and cost intensity, the generation of antibodies and assurance of their viral safety, and potential expression-interference or signal-saturation of the co-expressed fluorescent protein. To improve the method of fluorescent-protein co-expression, expression constructs were created that constitutively express a model vaccine antigen together with one of three fluorescent proteins having translation initiation controlled by a wildtype or mutant internal ribosome entry site (IRES), for a total of six constructs. The constructs were transfected into Chinese hamster ovary cells (CHO) cells, enriched for high fluorescence, cultured, and tested in a mini bioreactor to identify the most promising construct. The fluorescent protein, Fluorescent Ubiquitination-based Cell Cycle Indicator (FUCCI) with a mutant IRES performed best and was further tested with three additional vaccine antigens. Across the four vaccine antigens, the FUCCI fluorescent protein yielded productivity enhancements, without the need for generating an antibody and assuring its viral safety. Furthermore, FUCCI protein was present in negligible quantities in the cell supernatant, indicating a low risk for contaminating drug substances or vaccine antigen.


Asunto(s)
Cricetulus , Vacunas , Células CHO , Animales , Vacunas/genética , Proteínas Luminiscentes/genética , Proteínas Luminiscentes/metabolismo , Antígenos/genética , Antígenos/metabolismo , Transfección/métodos , Reactores Biológicos , Cricetinae
2.
PLoS One ; 7(4): e35623, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22558179

RESUMEN

A new transgenic mouse model for global increases in the Sodium Dependent Vitamin C transporter 2 (SVCT2) has been generated. The SVCT2-Tg mouse shows increased SVCT2 mRNA levels in all organs tested and correspondingly increased ascorbic acid (ASC) levels in all organs except liver. The extent of the increase in transporter mRNA expression differed among mice and among organs. The increased ASC levels did not have any adverse effects on behavior in the SVCT2-Tg mice, which did not differ from wild-type mice on tests of locomotor activity, anxiety, sensorimotor or cognitive ability. High levels of SVCT2 and ASC were found in the kidneys of SVCT2-Tg mice and urinary albumin excretion was lower in these mice than in wild-types. No gross pathological changes were noted in kidneys from SVCT2-Tg mice. SVCT2 immunoreactivity was detected in both SVCT2 and wild-type mice, and a stronger signal was seen in tubules than in glomeruli. Six treatments with Paraquat (3x10 and 3x15 mg/kg i.p.) were used to induce oxidative stress in mice. SVCT2-Tg mice showed a clear attenuation of Paraquat-induced oxidative stress in lung, as measured by F(2)-isoprostanes. Paraquat also decreased SVCT2 mRNA signal in liver, lung and kidney in SVCT2-Tg mice.


Asunto(s)
Ácido Ascórbico/metabolismo , Pulmón/metabolismo , Ratones Transgénicos/genética , Paraquat/farmacología , ARN Mensajero/biosíntesis , Transportadores de Sodio Acoplados a la Vitamina C/genética , Albúminas/metabolismo , Animales , Ansiedad/tratamiento farmacológico , Ansiedad/genética , Cognición/efectos de los fármacos , Cognición/fisiología , F2-Isoprostanos/metabolismo , Efecto Fundador , Riñón/efectos de los fármacos , Riñón/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Pulmón/efectos de los fármacos , Ratones , Ratones Transgénicos/metabolismo , Modelos Animales , Actividad Motora/efectos de los fármacos , Actividad Motora/genética , Especificidad de Órganos , Estrés Oxidativo/efectos de los fármacos , Transportadores de Sodio Acoplados a la Vitamina C/metabolismo , Regulación hacia Arriba
3.
Cell Cycle ; 6(21): 2697-705, 2007 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-17912037

RESUMEN

The ARF protein, encoded by alternate exon usage within the CDKN2A locus, provides a link between the retinoblastoma (pRb) and p53 tumor suppressor pathways. Agents that disable pRb or otherwise impinge on the E2F family of transcription factors induce expression of ARF, resulting in stabilization of p53 and activation of p53-regulated genes. However, in some cell types ARF is not induced upon cell cycle re-entry, as expected of a conventional E2F target gene, leading to the suggestion that the ARF promoter only responds to supra-physiological or aberrant levels of E2F. These properties have recently been attributed to a variant E2F binding site but attempts to map specific response elements within the ARF promoter have generally yielded confusing answers. Here we show that in IL2-dependent T-lymphocytes, ARF expression is induced as cells progress from G(0) into S phase, in parallel with other bona fide E2F target genes. This is accompanied by increased association of E2F1 with the endogenous ARF promoter. Our findings suggest that the ability of ARF to register normal proliferative cues depends on the levels of E2F generated in different settings and argue against the idea that it reacts exclusively to oncogenic signals.


Asunto(s)
Ciclo Celular/fisiología , Factores de Transcripción E2F/fisiología , Linfocitos T/citología , Linfocitos T/metabolismo , Proteína p14ARF Supresora de Tumor/biosíntesis , Proteína p14ARF Supresora de Tumor/genética , Secuencia de Bases , Línea Celular , Células Cultivadas , Humanos , Datos de Secuencia Molecular , Linfocitos T/fisiología
4.
EMBO J ; 21(12): 2936-45, 2002 Jun 17.
Artículo en Inglés | MEDLINE | ID: mdl-12065407

RESUMEN

The CDKN2A tumour suppressor locus encodes two distinct proteins, p16(INK4a) and p14(ARF), both of which have been implicated in replicative senescence, the state of permanent growth arrest provoked in somatic cells by aberrant proliferative signals or by cumulative population doublings in culture. Here we describe primary fibroblasts from a member of a melanoma-prone family who is homozygous for an intragenic deletion in CDKN2A. Analyses of the resultant gene products imply that the cells are p16(INK4a) deficient but express physiologically relevant levels of a frameshift protein that retains the known functions of p14(ARF). Although they have a finite lifespan, the cells are resistant to arrest by oncogenic RAS. Indeed, ectopic expression of RAS and telomerase (hTERT) results in outgrowth of anchorage-independent colonies that have essentially diploid karyotypes and functional p53. We find that in human fibroblasts, ARF is not induced demonstrably by RAS, pointing to significant differences between the proliferative barriers implemented by the CDKN2A locus in different cell types or species.


Asunto(s)
Senescencia Celular/fisiología , Inhibidor p16 de la Quinasa Dependiente de Ciclina/metabolismo , Fibroblastos/fisiología , Proteína p14ARF Supresora de Tumor/metabolismo , Proteínas ras/metabolismo , Adulto , Animales , Células Cultivadas , Niño , Inhibidor p16 de la Quinasa Dependiente de Ciclina/genética , Proteínas de Unión al ADN , Fibroblastos/citología , Fibroblastos/efectos de la radiación , Eliminación de Gen , Humanos , Hibridación Fluorescente in Situ , Masculino , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Telomerasa/genética , Telomerasa/metabolismo , Proteína p14ARF Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/metabolismo , Rayos Ultravioleta , Proteínas ras/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA